⌘K

Loading dashboard...

🚀 Emerging & Future Peptides

The cutting edge of peptide research: what's coming next in longevity, metabolic health, and performance optimization

Emerging

Research

Future

Clinical Trials

The Next Generation

This section covers peptides and compounds currently in clinical trials or advanced research. Some are available for research purposes, others will become available in the coming years. This is the bleeding edge of the field.

Development Pipeline Status

Research

Preclinical/Early stage

Phase 1-2

Safety & efficacy trials

Phase 3

Large-scale confirmation

Available

Can be obtained now

Compounds to Watch

Retatrutide

Triple Agonist (GLP-1/GIP/Glucagon)

Phase 3 Trials

The "next generation" after Tirzepatide. Triple receptor activation for maximum metabolic effect.

KEY FINDINGS:

•Phase 2: Up to 24.2% weight loss at 48 weeks
•Superior to Tirzepatide in early comparisons
•Glucagon component adds thermogenic effect

Expected FDA submission 2025-2026

SS-31 (Elamipretide)

Mitochondrial Peptide

Phase 3 Trials

Targets cardiolipin in mitochondrial membranes. Restores cellular energy production.

KEY FINDINGS:

•Improves mitochondrial function in aging
•Being studied for heart failure, Barth syndrome
•May enhance exercise capacity in elderly

FDA breakthrough therapy designation

Survodutide

Dual Agonist (GLP-1/Glucagon)

Phase 3 Trials

Boehringer Ingelheim's dual agonist with stronger glucagon activity than Tirzepatide.

KEY FINDINGS:

•Phase 2: 18.7% weight loss at 46 weeks
•Strong NAFLD/NASH improvements
•More thermogenic than pure GLP-1s

Phase 3 ongoing for obesity and NASH

Orforglipron

Oral GLP-1 Agonist

Phase 3 Trials

Small molecule oral GLP-1 (not a peptide). Could replace injectable semaglutide.

KEY FINDINGS:

•Phase 2: 14.7% weight loss at 36 weeks
•Daily oral pill (vs weekly injection)
•Similar efficacy to injectable semaglutide

Eli Lilly targeting 2025-2026

MOTS-c

Mitochondrial Peptide

Research

Mitochondria-derived peptide that mimics exercise. Improves metabolic homeostasis.

KEY FINDINGS:

•Exercise mimetic effects
•Improves insulin sensitivity
•May enhance longevity pathways

Available for research, human trials emerging

FGL (FG Loop Peptide)

Neuropeptide

Preclinical

NCAM-derived peptide for neuroregeneration. Potential for neurodegenerative diseases.

KEY FINDINGS:

•Promotes neurite outgrowth
•May aid TBI and stroke recovery
•Synergistic with BDNF pathways

Research compound

AOD-9604

GH Fragment

Available

Modified fragment of growth hormone (amino acids 177-191). Fat loss without GH side effects.

KEY FINDINGS:

•Targets fat metabolism directly
•No effect on IGF-1 or glucose
•TGA approved in Australia for osteoarthritis

Available via compounding pharmacies

Humanin

Longevity Peptide

Research

Mitochondria-derived peptide with cytoprotective and anti-apoptotic effects.

KEY FINDINGS:

•Protects against cellular stress
•May extend healthspan
•Elevated in centenarians

Research stage, limited clinical data

Key Emerging Categories

Next-Gen Metabolic Agents

Multi-receptor agonists that combine GLP-1, GIP, and glucagon signaling for unprecedented weight loss.

• Retatrutide: Triple agonist (GLP-1/GIP/Glucagon) - 24% weight loss
• Survodutide: Dual agonist with NASH benefits
• Orforglipron: Oral small molecule GLP-1

Mitochondrial Peptides

Target the powerhouse of cells directly. Implications for aging, energy, and disease.

• SS-31 (Elamipretide): Cardiolipin stabilization
• MOTS-c: Exercise mimetic effects
• Humanin: Cytoprotection and longevity

Cognitive & Neuro

Next-generation nootropics and neuroprotective compounds.

• FGL: NCAM-derived neuroregeneration
• P21: CNTF-derived neurotrophin
• Dihexa: Angiotensin IV analog for cognition

Longevity & Epigenetics

Compounds targeting the fundamental mechanisms of aging.

• Epitalon: Telomerase activation
• Humanin: Mitochondrial-derived cytoprotection
• FOXO4-DRI: Senolytic peptide

Expected Timeline

2024-25

Retatrutide Phase 3 completion

Eli Lilly's triple agonist expected to show definitive efficacy

2025

Orforglipron FDA submission

First oral small molecule GLP-1 could transform the market

2025-26

SS-31 potential approval

Mitochondrial peptide for specific indications

2026+

Next-gen compounds enter Phase 3

Quadruple agonists and novel mechanisms in development

Research Status Disclaimer

Many compounds discussed here are in clinical trials or preclinical research. They are not approved for human use outside of trials. Information is provided for educational purposes about the future direction of the field. Do not attempt to obtain or use unapproved compounds.

Loading dashboard...